


# First Quarter 2025 Earnings

revvity

April 28, 2025



# Safe Harbor

This presentation contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to statements relating to estimates and projections of future earnings per share, cash flow and revenue growth and other financial results, developments relating to our customers and end-markets, plans concerning business development opportunities, acquisitions or divestitures. Words such as "believes," "intends," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management's current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. A detailed description of these risk factors can be found under the caption "Risk Factors" in our most recent annual report on Form 10-K and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this presentation.

In addition to financial measures prepared in accordance with generally accepted accounting principles (GAAP), this presentation also contains non-GAAP financial measures. A reconciliation of these measures to the most directly comparable GAAP measures is included in the embedded [hyperlink](#) and is available on the "Financial Information" section of our website at [www.revvity.com](http://www.revvity.com).

# Key Takeaways

## Innovation

Expanded NGS partnership  
with **Genomics England**

Received **FDA approval** for  
more automated **latent TB**  
workflow

## Transformation

Leveraging **strong execution**  
and **balanced portfolio** to  
appropriately navigate dynamic  
macroeconomic environment


## Performance

Solid organic growth driven by  
**Diagnostics & Software**

**Strong synergy realization**  
&  
**Cash flow generation**


*A Scientific Solutions Company Helping To Solve The World's Greatest Health Challenges  
From Discovery To Development, and Diagnosis to Cure*

# 1Q25 Revenue Highlights





## Segments

● Diagnostics   ● Life Sciences




## Geographic

● AMERICAS   ● APAC   ● EU



## Product Mix

● Recurring   ● Non-recurring




# 1Q25 Financial Results

REVENUE	ADJUSTED OP MARGIN	ADJUSTED EPS	FREE CASH FLOW
\$665M	25.6%	\$1.01	\$118M
↑ +2% y/y	↑ +5bps y/y	↑ +4% y/y	
Organic: +4%   M&A: 0%   FX: -1%	Adj. Gross Margin: 61.7%   +80bps y/y	Adj. Tax Rate: 19.5%	YTD FCF % Adj. NI: 97%
		Adj. Net Interest & Other: \$18M	

# Life Sciences


● LIFE SCIENCE SOLUTIONS ● SOFTWARE



REVENUE	AJUSTED OP MARGINS
2% Organic Growth	31.1%
Reported: 1%   M&A: 0%   FX: -1%	+110bps y/y

- +LSD growth from Pharma/Biotech, -LSD decline from Academic/Gov't
- -LSD decline in Life Science Solutions; instrument declines partially offset by solid reagent growth
- +DD software growth driven by new orders, strong renewals and SaaS performance
- Margin expansion yr/yr driven by mix and synergies, partially offset by investments

# Diagnostics




REVENUE	ADJUSTED OP MARGINS
<b>5%</b> Organic Growth	<b>22.8%</b>
Reported: 3%   M&A: 0%   FX: -2%	-150 bps y/y


- +HSD ImmunoDX globally; +LSD in China
- +LSD Reproductive Health globally driven by strength in newborn
- Margin decline driven by strategic investments

# 2025 Financial Guidance

REVENUE	<b>\$2.83B - \$2.87B</b>
	Reported: 3% to 4%
	Organic: 3% to 5%
	FX: -0.5%, M&A: 0%
ADJUSTED OP. MARGIN	<b>27.9-28.1%</b>
ADJUSTED EPS	<b>\$4.90 - \$5.00</b>
	Adj. Net interest expense, other: ~\$75M
	Adjusted tax rate: ~19%
	Average diluted share count: 119M







Revvity.com